100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
1428243-28-0Upadacitinib Des TFEA Carbamate Impurity
● In Stock
| Catalogue No.: | VE0027848 |
|---|---|
| CAS No.: | 1428243-28-0 |
| Mol. Formula: | C21H23N5O2S |
| Mol. Weight: | 409.50 g/mol |
Additional information on CAS 1428243-28-0
Parent drug
UpadacitinibIUPAC Name
8-((3R,4S)-4- Ethylpyrrolidin-3-yl)-3-tosyl-3Himidazo[ 1,2-a]pyrrolo[2,3-e] pyrazinePharmacopeial Synonyms
N/ASynonyms
N/ASmiles
O=S(N1C=CC2=C1N=CC3=NC=C([C@H]4CNC[C@H]4CC)N32)(C5=CC=C(C)C=C5)=OInChI
InChI=1S/C21H23N5O2S/c1-3-15-10-22-11-17(15)19-12-23-20-13-24-21-18(26(19)20)8-9-25(21)29(27,28)16-6-4-14(2)5-7-16/h4-9,12-13,15,17,22H,3,10-11H2,1-2H3/t15-,17+/m1/s1Description
Upadacitinib Des TFEA Carbamate Impurity (CAS 1428243-28-0) is a process-related organic impurity associated with the upadacitinib synthetic route, arising from aberrant carbamoylation or loss of the tetrafluoroethylamine-derived side chain during intermediate conversion. With molecular formula C21H23N5O2S and molecular weight 409.50 g/mol, it reflects a structurally defined non-volatile component rather than a simple degradation product. Its characterization typically requires LC-MS/MS for molecular ion confirmation and LC-UV or HPLC with mass-sensitive detection for quantification, with orthogonal NMR support when needed. Because the impurity is route-specific, it is evaluated within impurity control and ICH M7 risk assessment frameworks as applicable.Request a Quote
"*" indicates required fields
Other products related to Upadacitinib impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
